Reduced glial fibrillary acidic protein and glutamine synthetase expression in astrocytes and Bergmann glial cells in the rat cerebellum caused by delta(9)-tetrahydrocannabinol administration during development.
In this study we analyzed the responses of cerebellar astroglial cells to pre- and perinatal delta(9)-tetrahydrocannabinol (THC) exposure in three postnatal ages and both sexes. To determine whether THC during development directly modifies astroglial growth, this study investigated the effects of THC on astroglial morphological changes and on the expression of specific astroglial markers (glial fibrillary acidic protein: GFAP and glutamine synthetase: GS). Our results demonstrated that the administration of THC during development has deleterious effects on astroglial maturation in the cerebellum. These results also indicate that THC might interfere with astroglial differentiation in a way dependent on sex. The effect of cannabinoids on the development of cerebellar astroglial cells (astrocytes and Bergmann glial cells) is to reduce protein synthesis, since both GFAP and GS decreased in astroglial cells, not only during THC exposure but also in adult ages. Our data suggest that pre- and perinatal THC exposure directly interferes with astroglial maturation by disrupting normal cytoskeletal formation, as indicated by the irregular disposition of GFAP and the lower GFAP expression observed at all the ages studied. THC exposure during development may also modulate glutamatergic nervous activity since GS expression is reduced in THC-exposed brains. GS expression increased progressively after THC withdrawal, but GS expression had still not reached control values two months after THC withdrawal. This indicates that glutamate uptake is lower in glial cells exposed to THC, since GS expression is lower than in older controls. Consequently, glutamatergic neurotransmission may be affected by cannabinoid exposure during gestation. Therefore, cannabinoids exert developmental toxicity, at least on astroglial cells, which could contribute to fetal brain growth retardation.
Suárez
I
I
Departamento de Biología Celular, Universidad de Alcalá, Spain. isabel.suarez.uah.es
Bodega
G
G
Fernández-Ruiz
J J
JJ
Ramos
J A
JA
Rubio
M
M
Fernández
B
B
D000818:Animals; D001253:Astrocytes / Q000187:drug effects / Q000378:metabolism; D015153:Blotting, Western; D002531:Cerebellum / Q000187:drug effects* / Q000196:embryology* / Q000378:metabolism; D013759:Dronabinol / Q000633:toxicity*; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000096:biosynthesis / Q000187:drug effects; D005970:Glutamate Synthase / Q000096:biosynthesis / Q000187:drug effects; D007150:Immunohistochemistry; D008297:Male; D009457:Neuroglia / Q000187:drug effects / Q000378:metabolism; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D011619:Psychotropic Drugs / Q000633:toxicity*; D051381:Rats; D012737:Sex Factors; D013997:Time Factors
D005904:Glial Fibrillary Acidic Protein; D011619:Psychotropic Drugs; D013759:Dronabinol; D005970:Glutamate Synthase